NEW therapies for treatment of
Alzheimers Disease (AD) have had
a failure rate of 99.6% getting to
Phase III level of the development
pipeline since 2002, US research
has found.
The study used the publicly
available www.clinicaltrials.gov
database to assess the historic
trends of AD drug development
and to put the current pipeline of
agents in perspective.
Currently, 108 trials of AD
therapies include only 94 unique
agents, a relatively small number
of test compounds considering
the enormity of the problem, the
authors said - CLICK HERE to read.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jul 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.